NASDAQ:MESO
Mesoblast Ltd Stock News
$7.35
+0.330 (+4.70%)
At Close: May 17, 2024
Mid-Day Market Update: Limelight Networks Falls Following Q1 Earnings; Mesoblast Shares Surge
04:00pm, Friday, 24'th Apr 2020
Midway through trading Friday, the Dow traded down 0.14% to 23481.83 while the NASDAQ rose 0.13% to 8505.65. The S&P also rose, gaining 0.07% to 2,799.73.
The U.S. is the...
Stocks That Hit 52-Week Highs On Friday
02:33pm, Friday, 24'th Apr 2020
During Friday's morning session, 28 stocks hit new 52-week highs.
Noteworthy Mentions:
The largest company by market cap to set a new 52-week high was Eli Lilly (...
Mid-Morning Market Update: Markets Mostly Flat; Verizon Profit Tops Estimates
02:15pm, Friday, 24'th Apr 2020
Following the market opening Friday, the Dow traded up 0.05% to 23527.17 while the NASDAQ fell 0.09% to 8487.46. The S&P also rose, gaining 0.05% to 2,799.17.
The U.S. is the...
CHK, BYND among premarket gainers
01:15pm, Friday, 24'th Apr 2020
Mesoblast (NASDAQ:MESO) +119% as cell therapy shows significant benefit in COVID-19 patients.Medigus (NASDAQ:MDGS) +73% on COVID-19 plan.Pluristem Therapeutics (NASDAQ:PSTI) +20% on €50 capital r
32 Stocks Moving in Friday's Pre-Market Session
11:11am, Friday, 24'th Apr 2020
Gainers
Abraxas Petroleum Corporation (NASDAQ: AXAS) shares rose 63.8% to $0.475 in pre-market trading after jumping 123% on Thursday.
FTS International, Inc. (NASDAQ: FTSI)...
Key points: 83% survival in ventilator-dependent COVID-19 patients (10/12) with moderate/severe acute respiratory distress syndrome (ARDS) treated with two.
Biotech ETFs Gaining on Progress in Coronavirus Treatment
11:04pm, Tuesday, 21'st Apr 2020
The race to introduce vaccine and treatment for coronavirus is opening up opportunities, making the biotech sector a prospective space for investments.
Abeona Therapeutics Appoints Brian Pereira and Shawn Tomasello to the Board of Directors
12:00pm, Tuesday, 21'st Apr 2020
NEW YORK and CLEVELAND, April 21, 2020 -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced appointments of Brian.
NEW YORK, April 17, 2020 -- Mesoblast Limited (Nasdaq: MESO; ASX:MSB) today announced that results using its allogeneic mesenchymal stem cell product candidate remestemcel-L in.
The Zacks Analyst Blog Highlights: Pluristem Therapeutics, Mesoblast, Gilead Sciences, Pfizer and Regeneron
12:35pm, Wednesday, 15'th Apr 2020
The Zacks Analyst Blog Highlights: Pluristem Therapeutics, Mesoblast, Gilead Sciences, Pfizer and Regeneron
The Zacks Analyst Blog Highlights: Pluristem Therapeutics, Mesoblast, Gilead Sciences, Pfizer and Regeneron
12:35pm, Wednesday, 15'th Apr 2020
The Zacks Analyst Blog Highlights: Pluristem Therapeutics, Mesoblast, Gilead Sciences, Pfizer and Regeneron
Pluristem Up on Cell Therapy Treatment of Coronavirus Patient
01:53pm, Tuesday, 14'th Apr 2020
Pluristem (PSTI) gains on the treatment of first patient suffering from COVID-19 complications with its cell therapy.
Will Stem Cell Therapies Aid in Fight Against Coronavirus?
12:37pm, Tuesday, 14'th Apr 2020
With the coronavirus outbreak gaining steam worldwide, pharma/biotech companies are evaluating every possible therapy to combat the spread.
Update: Mesoblast (ASX:MSB) Stock Gained 57% In The Last Year
11:46pm, Monday, 13'th Apr 2020
These days it's easy to simply buy an index fund, and your returns should (roughly) match the market. But investors...
More than 20 Companies Are Working on Coronavirus Treatments or Vaccines
06:27pm, Friday, 10'th Apr 2020
COVID-19 cases make up over 1,617,204 today, with 466,299 of them in the U.S. Over 20 companies are working on coronavirus vaccine or drugs.
